NCT03688685 - A Clinical Study to Evaluate CAD-1883 in Essential Tremor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

September 10, 2019

Study Completion Date

September 24, 2019

Conditions

Essential Tremor

Interventions

DRUG

CAD-1883

Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.

Trial Locations (7)

Cadent Investigational Site, Hallandale

Cadent Investigational Site, Anniston

Cadent Investigational Site, Dayton

Cadent Investigational Site, Farmington Hills

Cadent Investigational Site, St Louis

Cadent Investigational Site, Rogers

Cadent Investigational Site, San Diego